MedTrace Logo

Bisphosphonate Therapy in MONA Spectrum Disorder

NCT02823925 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2016-07-06

No results posted yet for this study

Summary

Multicentric osteolysis, nodulosis and arthropathy (MONA) spectrum disorder is a rare inherited progressive skeletal disorder caused by mutations in the matrix metalloproteinase 2 (MMP2) gene. Treatment options are limited. The investigators reviewed the outcome of patients affected with MONA and treated with intravenous bisphosphonates in the clinical Center.

Conditions

  • Bone Density
  • Pain
  • Fracture

Interventions

DRUG

Pamidronate or Zoledronate

Sponsors & Collaborators

  • Medical University Innsbruck

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02823925 on ClinicalTrials.gov